Two studies underlined circulating tumor DNA’s growing clinical role. The phase 2 RETAIN‑2 trial from Fox Chase Cancer Center showed a blood‑based ctDNA assay can stratify muscle‑invasive bladder cancer patients and identify those who may safely skip immediate cystectomy after bladder‑preserving therapy. The trial used ctDNA to predict metastatic risk and guide conservative management. In a complementary multicenter study, investigators demonstrated that ctDNA profiling can guide FGFR‑targeted therapy decisions in metastatic urothelial cancer, showing that liquid biopsy may match or outperform tissue testing for certain actionable alterations. Both studies were published in leading journals and reported at recent oncology meetings. Together, the data support faster, less invasive biomarker-driven decisions in urothelial cancer and add to evidence pushing ctDNA toward routine use for therapy selection and surveillance.